John Gebeily
Head of Equities @ Audi Capital
London, United Kingdom
John Gebeily is a seed investor at Audi Capital in London focused on Health Care and Biotechnology. Dr John Gebeily is Partner at Kadmos Capital.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries John Gebeily invests in
Stages John Gebeily invests in
Countries John Gebeily invests in
Investment Focus
Industry
- Health Care 2 (29%)
- Biotechnology 2 (29%)
- Robotics 1 (14%)
- Software 1 (14%)
- Life Science 1 (14%)
Stage
- Seed 4 (57%)
- Series A 1 (14%)
- Venture - Series Unknown 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Antiverse
|
Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to happen more quickly and cost-effectively. It is dedicated to engineering the future of drug development to change the course of people'slives. | $9.3M / Series A / Mar 03, 2026 | |
GlycanAge
|
Can you slow down your inner body clock? At GlycanAge we’ve proven you can! How? By analysing over 150,000 individuals across 20 years of research from our world leading scientists.Our studies show that well managed dietary improvements, healthy weight loss, and exercise can tangibly improve your biological age. GlycanAge is the only biologicalage test proven to respond to lifestyle changes. We’ve made your choices measurable so you can stay healthier and younger for longer. | $8.7M / Venture - Series Unknown / Dec 18, 2025 | |
iFast Diagnostics
|
iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $6.5M / Seed / Nov 04, 2024 | |
|
Antiverse
|
Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to happen more quickly and cost-effectively. It is dedicated to engineering the future of drug development to change the course of people'slives. | $4.6M / Seed / Oct 15, 2024 | |
|
GlycanAge
|
Can you slow down your inner body clock? At GlycanAge we’ve proven you can! How? By analysing over 150,000 individuals across 20 years of research from our world leading scientists.Our studies show that well managed dietary improvements, healthy weight loss, and exercise can tangibly improve your biological age. GlycanAge is the only biologicalage test proven to respond to lifestyle changes. We’ve made your choices measurable so you can stay healthier and younger for longer. | $4.2M / Seed / Feb 19, 2024 | |
|
iFast Diagnostics
|
iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $2.4M / Seed / Feb 16, 2023 | |
cheMastery
|
CheMastery is a company that creates laboratory automation technology. They provide automation solutions for chemical laboratories in order to facilitate the manufacturing and R&D processes in the chemical sector. It makes science more effective and reliable for scientists in the chemical sector. | Seed / Nov 13, 2022 |
Co-Investors
About Audi Capital
Audi Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
John Gebeily
Head of Equities
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does John Gebeily invest in?
John Gebeily invests primarily in Health Care, Biotechnology and Robotics startups, most often at Seed and Series A stage. Most of the 7 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did John Gebeily last invest?
The most recent investment recorded for John Gebeily closed in Mar 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
